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Abstract
The goal of this research was to establish a new and innovative framework for cost-effec-
tiveness modeling of HIV-1 treatment, simultaneously considering both clinical and epide-
miological outcomes. EPICE-HIV is a multi-paradigm model based on a within-host micro-
simulation model for the disease progression of HIV-1 infected individuals and an agent-
based sexual contact network (SCN) model for the transmission of HIV-1 infection. It
includes HIV-1 viral dynamics, CD4+ T cell infection rates, and pharmacokinetics/pharma-
codynamics modeling. Disease progression of HIV-1 infected individuals is driven by the
interdependent changes in CD4+ T cell count, changes in plasma HIV-1 RNA, accumulation
of resistance mutations and adherence to treatment. The two parts of the model are joined
through a per-sexual-act and viral load dependent probability of disease transmission in
HIV-discordant couples. Internal validity of the disease progression part of the model is
assessed and external validity is demonstrated in comparison to the outcomes observed in
the STaR randomized controlled clinical trial. We found that overall adherence to treatment
and the resulting pattern of treatment interruptions are key drivers of HIV-1 treatment out-
comes. Our model, though largely independent of efficacy data from RCT, was accurate in
producing 96-week outcomes, qualitatively and quantitatively comparable to the ones
observed in the STaR trial. We demonstrate that multi-paradigm micro-simulation modeling
is a promising tool to generate evidence about optimal policy strategies in HIV-1 treatment,
including treatment efficacy, HIV-1 transmission, and cost-effectiveness analysis.
Introduction
As a result of the introduction of increasingly potent and safe anti-retroviral therapy (ART),
over the last decade HIV-1 infection has largely become a manageable disease, with mortality
rates approaching those of the general population in many countries [1–3]. Similar to other
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pharmaceutical drugs, before marketing authorization, efficacy and safety profiles of new anti-
retroviral regimens are usually investigated exclusively in clinical trial settings.
Most current clinical trials on HIV-1 ART follow a predefined schedule of follow-up visits
rarely spaced more than 2 to 3 months apart, with quite rapid confirmation of virologic failure
and drug withdrawal after initial detection [4–7]. Common clinical trial efficacy endpoints and
their algorithms (e.g. the percentage of virologically suppressed patients at a certain time win-
dow, determined by the FDA Snapshot algorithm) are crucially dependent on these pre-speci-
fied follow-up protocols [4, 5, 7, 8]. International HIV-1 treatment guidelines, however,
suggest follow-up visits for plasma HIV-1 RNA viral load assessment every 3 to 6 months
(with more frequent monitoring only at the start of ART) and confirmation of virologic failure
1 to 2 months later [9]. Moreover, in clinical practice, much heterogeneity tends to be observed
with respect to the monitoring of ART, and subjects on stable and suppressive regimens are
commonly seen every 6 months [10, 11].
Despite efforts to raise patient´s adherence [12–16], in clinical practice it continues to be
lower in comparison to clinical trials [17, 18]. For many patients it may be quite difficult to
maintain a high level of adherence, necessary to achieve durable viral suppression, over the
life-time course of a chronic disease [19–23]. Suboptimal adherence not only limits the effec-
tiveness of therapy in terms of viral suppression, but also facilitates the replication and selec-
tion of resistant mutant viral strains, often limiting subsequent ART options [24, 25]. HIV
resistance drug resistance has further become a relevant public health issue, as HIV-1 resis-
tance mutations can be transmitted to other individuals [26].
Due to the heterogeneity observed in real-life monitoring schedules and adherence patterns,
basing cost-effectiveness models for HIV-1 treatment mainly on the efficacy observed in clini-
cal trials has the potential of leading to biased estimates of true effectiveness. Moreover, for
drugs whose public use has only recently been authorized, little to no data might be available
from observational studies, further restricting modeling options.
State of the art cohort and micro-simulation cost-effectiveness models for HIV-1 treatment
typically focus on clinical outcomes such as viral suppression, life expectancy, causes of death,
opportunistic infections and time on treatment [27–31]. Many of these models lack the ability
of quantifying the impact of different treatment regimens and adherence behavior on the trans-
mission of HIV-1 and HIV-1 drug resistance [27–31].
Some models that include transition modules tend to do so in a mostly deterministic, non-
dynamic nature, making use of systems of ordinary differential equations. These models are
capable of distinguishing between different populations (uninfected, infected, heterosexual,
homosexual, injection drug users), linking them through pathway-dependent infection rates,
but lack the ability to capture important population behavioral heterogeneity [27, 29, 31].
In this paper, we present EPICE-HIV, an epidemiologic cost-effectiveness model for HIV-1
treatment, designed to produce qualitatively and quantitatively credible results without overly
depending on outcomes of clinical trials and observational studies. EPICE-HIV is a multi-para-
digm model based on a within-host micro-simulation for the disease progression of HIV-1
infected individuals and an agent-based sexual contact network (SCN) model for the transmis-
sion of HIV-1 infection (transmission module). The two parts of the model are joined through
a per-sexual-act, plasma HIV-1 RNA viral load dependent probability of HIV-1 transmission
in serodiscordant couples and a CD4+ T cell count dependent mortality rate.
Since the algorithm driving the HIV-1 transmission module has been described and vali-
dated previously in the context of sexually transmitted diseases [32], this paper will focus on the
within-host model of EPICE-HIV, in which disease progression is driven by adherence to ART
and the interdependent changes in CD4+ T cell counts and plasma HIV-1 RNA levels. For vali-
dation purposes, a simulation study was set up to investigate the effectiveness of once daily
EPICE-HIV a Micro-Simulation Model for HIV
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treatment with rilpivirine 25mg (RPV), emtricitabine 200mg (FTC) and tenofovir DF 245mg
(TDF) as initial ART, mimicking the conditions and population of the STaR study [5, 33].
Material and Methods
In the within-host model (Fig 1), adherence to the ART regimen of primary interest is modeled
using a binary autoregressive model, assuming adherence on any given day is conditional on
adherence on the previous day. A per-drug, one-compartment, pharmacokinetics model (PK)
followed by a pharmacodynamics model (PD), link adherence to a progressive HIV-1 dynam-
ics model (HIV-D) generating time dependent plasma concentrations of free virus and unin-
fected and infected CD4+ T cells. Treatment regimens of secondary interest are modeled
connecting a previously published discrete event simulation (DES) model for HIV-1 treatment
[34] to the HIV-D model.
Basic HIV-1 Dynamics Model
The HIV-D model consists of four populations: uninfected CD4+ T cells (T1), productively
infected activated CD4+ T cells (T2), latently infected resting CD4
+ T cells (L) and HIV-1 viri-
ons (V) [35]. Initially, only uninfected target CD4+ T cells (T1) and HIV-1 virions (V) are pres-
ent in the system (Table 1).
HIV-1 virions can infect target CD4+ T cells, a process modeled through a commonly used
“mass-action” term kT1VT1, with kT1 the target CD4
+ T cell infection-rate by free virus. Upon
infection, a small fraction αL of CD4
+ T cells will result in latently infected CD4+ T cells (L),
not actively producing HIV-1 virions. The remaining fraction of infections results in
Fig 1. Diagram of the within-host model for disease progression of HIV-1 infected individuals. For the treatment regimen of primary interest (blue
diagram), the adherence model dictates the daily intake of ART. Through a pharmacokinetic (PK) and pharmacodynamic (PD) model, the plasma drug
concentration and drug effect are determined. Drug effect influences the inter-dependent and time-evolving plasma HIV-1 RNA level and CD4+ T cell count
in the basic HIV-1 dynamics model (HIV-D). For treatment regimens of secondary interest (orange diagram), a discrete event simulation model (DES)
determines the plasma HIV-1 RNA level over time. Using the dynamics of the HIV-D model, CD4+ T cell counts are updated accordingly.
doi:10.1371/journal.pone.0149007.g001
EPICE-HIV a Micro-Simulation Model for HIV
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productively infected CD4+ T cells (T2). Latently infected CD4
+ T cells are activated into pro-
ductively infected cells at a constant rate αL.
All cells have a finite lifespan, determined by death-rates dT1 ; dT2 and δL for uninfected, pro-
ductively infected and latently infected CD4+ T cells, respectively. For HIV-1 virions, the
death-rate is given by δV. Source rates of uninfected CD4
+ T cells (fssT1) and HIV-1 virions
(fppvT2), drug potency (ε) and persistent low level viremia (VMin) are discussed further on in
this section.
The following system of ordinary differential equations, of which a graphical illustration is
given in Fig 2, represents the resulting rate of change in the concentration of cells for each of
Table 1. Basic HIV-Dmodel populations and initial values [35].
Population Description Initial value
T1 Uninfected CD4+ T cells 1,000 cells/mm3
T2 Productively infected CD4+ T cells 0 cells/mm3
L Latently infected CD4+ T cells 0 cells/mm3
V HIV-1 virions‡ 0.001 virions/mm3
‡ Corresponding to 2 plasma HIV-1 RNA copies/mL.
doi:10.1371/journal.pone.0149007.t001
Fig 2. Stock and flow diagram of the basic HIV-1 dynamics model, modified from Rong et al [35]. Uninfected CD4+ T cells (T1) are produced at a rate
f ssT1 . Infected CD4+ T cells are produced at a rate kT1VT1, following mass-action kinetics between free virions (V) and uninfected CD4+ T cells. A small
fraction αL of infections results in latently infected resting CD4+ T cells (L). The remaining fraction results in productively infected activated CD4+ T cells (T2).
Latently infected CD4+ T cells are activated into productively infected cells at a constant rate aL. Free virions are produced by productively infected CD4+ T
cells at a rate fppvT2.
doi:10.1371/journal.pone.0149007.g002
EPICE-HIV a Micro-Simulation Model for HIV
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the four modelled populations:
dT1
dt
¼ fssT1  ð1 εÞkT1VT1  dT1T1
dT2
dt
¼ ð1 aLÞð1 εÞkT1VT1  dT2T2 þ aLL
dL
dt
¼ aLð1 εÞkT1VT1  dLL aLL
dV
dt
¼ fppVT2  dVV þ dVVMin:
ð1Þ
Disease Progression. During the first stage of HIV-1 infection (acute infection), in the
absence of treatment, large amounts of virus are being produced, destroying CD4+ T cells in
the process. As a result, CD4+ T cell counts drop rapidly and viral load levels spike. At the end
of this stage CD4+ T cell counts begin to increase, but do not return to pre-infection levels. At
the same time, plasma viral loads drop back down and settle into a viral set-point after a couple
of months, remaining at more stable levels thereafter. HIV-1 infection then moves into a clini-
cal latency stage, in which HIV-1 continues reproducing, but at much lower levels than during
the acute stage. This stage, though very variable, typically lasts about 8–10 years and is charac-
terized by a slow depletion of CD4+ T cells and late stage increase in plasma viral load [36–38].
Over time the efficiency in viral production increases due to different factors, including the
progressive loss by the immune system of the ability to contain viral production. In the model,
this is implemented by applying a time-dependent replication increase factor (fp) to the initial
viral production rate (pv) of productively infected CD4
+ T cells (T2) [39]. Furthermore, since
HIV-1 infection is known to eventually exhaust the body’s capacity to produce new uninfected
CD4+ T cells, a time-dependent capacity reduction factor (fs) is also applied to the base CD4
+ T
cell source rate (sT1) [39].
Both adjustment factors (fp and fs) depend on a measure for the total viral burden accumu-
lated over time since the start of infection, as
fs ¼ ð1þ QÞ1
fp ¼ 1þ pQ
ð2Þ
whereQ represents aWeibull cumulative distribution function on the viral burdenVb, the area
under the curve of the time evolving virion concentration Vwith respect to reference valueVref [39]:
QðVbÞ ¼ 1 exp 
Vb
s
 k" #
VbðtÞ ¼
1
Vref
ðt
0
VðxÞdx:
ð3Þ
The effect of specific incumbent period determinants that may affect disease progression
(e.g. age at infection, the presence of other sexually transmitted diseases) have not been
included in the current paper and will be addressed in future work.
Drug Potency. Anti-retroviral drugs within different classes (nucleoside reverse transcrip-
tase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), protease
inhibitors (PI), etc.) act on different points in the complex viral replication process in CD4+ T
cells. In order not to overly complicate the HIV-D model, an overall effect of ART on plasma
CD4+ T cell and HIV-1 virion concentrations was assumed. This overall drug effect or drug
EPICE-HIV a Micro-Simulation Model for HIV
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potency ε represents the percentage of new cell infections inhibited and acts upon the mass-
action term kT1VT1 by reducing the rate kT1 at which uninfected target CD4
+ T cells are infected
by free virus [35].
The analysis of viral decay following initiation of ART shows that plasma HIV-1 RNA levels
typically decline in three distinct phases [35]. In the model, to simulate the second phase decay,
a population of latently infected CD4+ T cells was considered, with a much lower decay rate
than the productively infected CD4+ T cells.
Persistent Low Level Viremia. Studies with especially sensitive assays [40] have demon-
strated that the second phase decay typically brings plasma viral loads down to a new quasi-
steady state below the 50 plasma HIV-1 RNA copies/mL threshold, with an average of persis-
tent low level viremia of around 3 copies/mL [41]. This could reflect the release of viruses from
other stable reservoirs, potentially outside of the plasma, which are unaffected by treatment
intensification. To accomplish a persistent low level of viremia in the model, an extra term
δVVmin was added to the rate of change in concentration of virions, representing the potential
inflow of free viruses from external reservoirs.
The level of persistent low viremia correlates well with pre-therapy plasma HIV-1 RNA lev-
els, more than with specific treatment regimens, even though some reports have linked PI with
higher rates of low level viremia than NNRTI [42]. Moreover, longitudinal analysis revealed no
significant decline in the level of persistent viremia over time (60–110 weeks), while on sup-
pressive ART. As a result of this, the HIV-D model assumes that the level of persistent low-
viremia under ART (represented by the parameter Vmin) remains constant over time and
depends only on pre-therapy plasma HIV-1 RNA levels, through a log-normal model fitted to
data presented in Maldarelli et al. (2007) [41]. The results of this analysis are presented in
Table 2 and show a highly significant effect of pre-therapy plasma HIV-1 RNA levels (log10
copies/mL) on persistent low-level viremia.
Between-Patient Variability. Between-patient variability in cell concentrations in plasma
has been introduced by exploiting the stable-state solution of the untreated (ε = 0), disease pro-
gression free (fp = 1 and fs = 1) system of ordinary differential equations. For untreated individ-
uals, the contribution of the latently infected CD4+ T cell population to plasma HIV-1 RNA
levels is negligible. Ignoring the presence of latently infected CD4+ T cells, two key parameters
of the HIV-D model, the HIV-1 infection rate of CD4+ T cells (kT1) and the viral production
rate (pV), can be written as a function of the stable-state plasma concentrations of target CD4
+
T cells (T 1) and HIV-1 virions ( V ), as
kT1 ¼
sT1  dT1 T 1
V T 1
pV ¼
dVdT2
kT1
T 1
:
ð4Þ
Table 2. Log-normal model parameter estimates for on-therapy plasma HIV-1 RNA levels as a function
of baseline pre-therapy plasma HIV-1 RNA levels.
Parameter Coefﬁcient P-value
Constant -2.700 <0.001
Pre-therapy plasma HIV-1 RNA (log10 copies/mL) 0.772 <0.001
Scale 1.25
doi:10.1371/journal.pone.0149007.t002
EPICE-HIV a Micro-Simulation Model for HIV
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Both productively infected activated and latently infected resting CD4+ T cells represent
only a residual fraction of the total CD4+ T cell population. As a result, the total CD4+ T cell
plasma concentration (T) can be approximated by the target CD4+ T cell population (Tﬃ T1).
Between-patient variability in plasma cell concentrations over time can then be controlled by
allowing for variability in model parameters kT1 and pV, substituting the desired viral set-point
HIV-1 virion (Vs) and total CD4
+ T cell (Ts) concentrations for V and T 1 in the equations
above.
Model Parameters. All base parameters relevant to the HIV-D model can be found in
Table 3. Most parameters were initially taken from the literature [35, 39, 43]. Some were recali-
brated to suit the purpose of modeling HIV-1 disease progression.
Many different values can be found in the literature for the viral production rate (pV) and
the HIV-1 infection rate of CD4+ T cells (kT1). For the base-case examples, presented through-
out the paper, the viral production rate (pV) was ﬁxed [35]. The HIV-1 infection rate (kT1) was
calibrated, from within a realistic range of values [35], as for stable-state CD4+ T cells count
and HIV-1 viral load to present suitable values (Fig 3). In the section on between-patient vari-
ability, it has been explained how these two parameters can be varied to introduce variability in
stable-state CD4+ T cell counts and HIV-1 viral loads for different patients.
The remaining parameters that were subject to recalibration are related to the HIV-1 disease
progression module. The conceptual model for disease progression was taken from a paper on
co-infection with HIV-1 and tuberculosis, based on a different HIV-1 dynamics model [39].
Recalibration of the model parameters was necessary to result in a realistic CD4+ T cell decline
and HIV-1 viral load increase over time (Fig 3 in the results section).
Disease Monitoring. Not all individuals in the simulated population are forced to perform
regular HIV-1 testing. For those that do, HIV-1 testing is assumed to follow a Poisson process,
Table 3. Parameter values used in the basic HIV-Dmodel.
Parameter Description Value Source
sT1 Source rate of uninfected CD4+ T cells 10 cells/mm
3/day [35]
kT1 HIV-1 infection rate of CD4+ T cells 0.00036/virion/day
‡,¥ [35]
δT1 Death rate of uninfected CD4+ T cells 0.01/day [35]
αL Percentage of latently infected CD4+ T cells 0.0015 [43]
δT2 Death rate of productively infected CD4+ T cells 0.7/day [35]
aL Activation rate of latently infected CD4+ T cells 0.01/day [43]
δL Death rate of latently infected CD4+ T cells 0.004/day [43]
pV Viral production rate 70 virions/day/cell‡ [35]
δV Death rate of virions 23/day [35]
Vref Viral load reference level 100.000¥ [39]
σ Scale parameter of Weibull CDF Q(Vb) 5
¥ [39]
k Shape parameter of Weibull CDF Q(Vb) 2¥ [39]
p Viral production rate increase parameter 40¥ [39]
ε Drug potency (% of new infections inhibited) Variable*
VMin Minimal viral load (for persistent low viremia) Variable†
‡ See “between-patient variability”;
* See “PK/PD modeling”;
† See “persistent low viremia”;
¥ Recalibrated
doi:10.1371/journal.pone.0149007.t003
EPICE-HIV a Micro-Simulation Model for HIV
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with exponential times between consecutive tests. Upon being diagnosed, a fraction of infected
individuals may choose not to seek treatment. For those who do seek treatment, regular medi-
cal visits are programmed in which CD4+ T cell counts and plasma HIV-1 RNA levels are
monitored until a patient is considered eligible for treatment (e.g.: CD4+ T cell count below
500 or 350 cells/mm3 [9, 44]).
The model is completely flexible with respect to disease monitoring parameters, making it
possible to investigate the effect on results of different hypotheses in terms of patients’ willing-
ness to test, willingness to be treated, monitoring frequency and treatment eligibility.
Primary Treatment Regimen Model
Adherence to Therapy. A quantitative relationship can be observed between the duration
of the longer treatment interruption and the average adherence level [45], in which treatment
interruptions of 30 or more days are not unusual for patients with an average adherence
between 40% and 60%. Furthermore, there is a differential impact of adherence and treatment
interruptions on the risk of virologic rebound (> 400 plasma HIV-1 RNA copies/mL) when
comparing NNRTI- based ART to ritonavir-boosted (PI/r) based ART [45]. For NNRTI, due
to their long terminal pharmacokinetic tail, at low-to-moderate adherence levels, sustained
treatment interruptions pose a greater risk of virologic rebound than a comparable number of
interspersed missed doses. On the other hand, PI/r average adherence rather than consecutive
missed doses is found to be associated with virologic rebound. In raltegravir-based regimens
longer treatment interruption and average adherence were both independently associated with
virological failure [46]. Lastly, and most importantly, the quantitative relationship between the
longer treatment interruption and the average adherence level seems to depend little on specific
treatment regimens [45].
The correct modeling of the daily adherence process, in order to capture the delicate rela-
tionship between treatment interruptions and average adherence, is of utmost importance.
Assuming adherence is a memoryless process may be misleading because the probability of a
treatment interruption of 30 or more days, related to an average adherence of 50%, is almost
non-existing. As such, in EPICE-HIV, adherence is modeled using a binary autoregressive
model, assuming adherence on any given day is a random process, conditional on adherence
on the previous day.
It depends on two key parameters: the probability of taking drugs on the current day, given
drugs were skipped the previous day (p10) or not (p11). For each individual in the simulated
Fig 3. Evolution of plasma HIV-1 RNA levels and CD4+ T cell counts in an untreated subject. Left: Plasma HIV-1 RNA levels as a function of time,
simulated by the HIV-D model accounting for disease progression. Right: corresponding CD4+ T cell counts. The model simulates the 3 typical stages of HIV-
1 infection: acute infection, clinical latency and AIDS phase. Dashed grey lines represent the HIV-D model without disease progression, the stable-state
solution of which is exploited to introduce between-patient variability in plasma cell concentrations.
doi:10.1371/journal.pone.0149007.g003
EPICE-HIV a Micro-Simulation Model for HIV
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population, an expected average adherence level (αAdh) is sampled from a pre-defined empiri-
cal or theoretical population-level distribution. Given this adherence level, the parameters p10
and p11 are then determined randomly for each individual as
p10  Uð0:10; 1:00Þ if aAdh  0:80;
p10  U 0;min 0:25;
aAdh
1 aAdh
  
if aAdh  0:80;
p11 ¼ 1þ p10 
p10
aAdh
:
ð5Þ
Here, p10 is sampled from one of two possible continuous uniform distributions, conditional
on the expected average adherence level being inferior or superior to 80%. The uniform distri-
butions were calibrated as to result in a qualitatively representative simulated relationship
between the longer treatment interruption and average adherence [45]. No formal calibration
techniques were used. p11 Is determined as a function of p10 and αAdh to ensure that the adher-
ence level of each individual converges over time to the pre-specified average adherence level
αAdh.
PK/PDModeling. Normalized drug concentrations Cn(t) = C(t)/IC50 (with C(t) the drug
concentration and IC50 the 50% inhibitory concentration against wild-type virus) are modeled
as a function of time as in [47] using the impulsive differential equation:
dCn
dt
¼  wCCn ; t 6¼ ti; ðno dose takenÞ;
CnðtþÞ ¼ CnðtÞ þ Cn;sd; t ¼ ti; ðdose takenÞ:
ð6Þ
Normalized concentration Cn(t) is assumed to increase instantaneously by a single amount
(Cn,sd) every time-point τi (for i = 1,2, . . .) a dose is taken, while in between doses Cn(t) decays
exponentially with a certain rate wC. For most commercially available antiretroviral drugs, val-
ues are available for their 50% inhibitory concentration (IC50), plasma half-life (t1/2), required
dosing interval (δτ = τi+1−τi) and related maximum concentration (Cmax). These values allow
for wC and Cn,sd to be determined as follows:
wC ¼
lnð2Þ
t1=2
;
Cn;sd ¼
Cmax
IC50
ð1 ewCdtÞ:
ð7Þ
The drug-potency εwt against wild-type HIV-1 virus for a given drug is modeled as a func-
tion of its normalized concentration using a Hill type dose-response curve [48]:
1 εwt ¼
1
Cmn þ 1
; ð8Þ
representing the fraction of new infections unaffected by the drug. A logarithmic measure of
inhibition Fwt can be deﬁned from this equation, as
Fwt ¼ log
εwt
1 εwt
 
¼ m logðCnÞ : ð9Þ
The slope parameterm of the linearized dose-response curve has greatly been ignored when
describing the antiviral activity of therapy in HIV-1 infection, but is of great importance to
determine inhibition at clinical drug concentrations (Cn 1) [49].
EPICE-HIV a Micro-Simulation Model for HIV
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For combination therapy, drug potency interaction effects can readily be modeled, starting
from the individual normalized drug concentrations, through Loewe additivity or Bliss inde-
pendence [49]. Loewe additivity assumes drugs have similar mechanisms or compete for the
same binding site. For a three-drug version of the Loewe additivity model, drug potency εwt,L
can be described by the equation:
1 ¼ C1;n
1 εwt;L
εwt;L
 ! 1
m1 þ C2;n
1 εwt;L
εwt;L
 ! 1
m2 þ C3;n
1 εwt;L
εwt;L
 ! 1
m3
:
ð10Þ
Bliss independence assumes independent action between drugs, such that the combined
effect εwt,B of triple combination therapy can be written as the product of the fractions unaf-
fected by each individual drug:
1 εwt;B ¼
1
Cm11;n þ 1
 1
Cm22;n þ 1
 1
Cm33;n þ 1
: ð11Þ
It predicts higher inhibition than Loewe additivity, especially at clinical drug concentrations.
Inhibition less than the Loewe prediction represents antagonism, whereas a combined effect
significantly greater than the Bliss prediction represents synergy.
The inhibitory effect of drug combinations are characterized on a spectrum defined by two
states, independent inhibition (Bliss independence) and competitive binding (Loewe additiv-
ity), with synergistic and antagonistic interactions at either extreme [49], as
Fwt;DI ¼ Fwt;L þ DI  ðFwt;B  Fwt;LÞ: ð12Þ
where Fwt,DI, Fwt,L and Fwt,B follow the deﬁnition of the previously introduced logarithmic mea-
sure of inhibition. Here, DI represents an index that quantiﬁes the degree of independence,
with DI = 0 corresponding to Loewe additivity and DI = 1 to Bliss independence.
The inhibitory potential at clinical drug concentrations for pairwise and triple combinations
of 19 commonly used antiretrovirals were analyzed, allowing for quantitative comparison of
antiviral activity of different drug regimens at expected plasma concentrations [49]. The results
of this analysis in terms of DI index estimates can be used to determine the combined inhibi-
tion effect of different drug regimens in the spectrum defined by Bliss independence and
Loewe additivity.
A summary of key PK/PD modeling quantities can be found in Table 4.
Table 4. Key PK/PDmodeling quantities.
Quantity Description
C(t) Drug concentration, as a function of time
IC50 50% Inhibitory concentration (against wild-type virus)
Cn(t) Normalized drug concentration, as a function of time
Cn,sd Instantaneous single dose increase in normalized drug concentration
wC Exponential decay rate of normalized drug concentration
εwt Drug potency (against wild-type virus), Cn dependent
Fwt Logarithmic function of inhibition (against wild-type), Cn dependent
m Slope parameter of logarithmic function of inhibition (Fwt)
DI Degree of independence
Loewe additivity DI = 0
Bliss independence DI = 1
doi:10.1371/journal.pone.0149007.t004
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Disease Monitoring. Viral suppression is checked for the first time at 1–2 months for a
patient starting a new ART and every 4–6 months thereafter, following international treatment
guidelines [9, 44]. If HIV-1 viral load is suppressed (<50 plasma RNA copies/mL), regular
medical follow-up visits are programmed for plasma HIV-1 RNA and CD4+ T cell count moni-
toring. If on any of these medical visits plasma HIV-1 RNA is no longer suppressed, a confir-
mation visit is scheduled (e.g. one month after [9]). If plasma HIV-1 RNA continues non-
suppressed, the patient is defined as having a virologic failure and moves to a subsequent treat-
ment line. If plasma HIV-1 RNA is suppressed again, the patient maintains its current treat-
ment regimen and returns to regular medical follow-up visits. Any time during the treatment,
a patient can switch a regimen due to adverse events or other non-virologic reasons. Time to
event distributions are considered for these regimen switches.
Costs. Daily costs for each of the components in the modeled ART are quantified indepen-
dently and accumulated continuously (dependent on adherence) for ART cost identification
purposes. For non-ART costs (e.g. non-ART medication, examinations and laboratory tests)
the model follows the same rules as for secondary treatment regimens discussed below. The
same holds for the simulation of hospitalizations and corresponding costs.
Secondary Treatment Regimens Model
Suppressive Therapy. Modeling of suppressive therapy for regimens of secondary interest
is based on an adaptation of a DES-based cost-effectiveness model [34]. Conditional on a num-
ber of patient-specific characteristics (age, gender, regimen characteristics, resistance level, etc.)
the time to the occurrence of 5 clinical events is estimated:
• Viral suppression (plasma HIV-1 RNA<50 copies/mL)
• Regimen switch due to virologic failure
• Regimen switch not due to virologic failure (e.g.: toxicity)
• Resistance development
• Hospitalization
This section provides a concise description of the modeling steps. Further details can be
found in the original publication [34].
Weibull distributions are considered for the estimation of event times for each of the clinical
events. Upon the occurrence of any event (except hospitalization), time to occurrence of all
events is updated using a conditional distribution approach. Virologic failure is defined as a
confirmed plasma HIV-1 RNA level>50 copies/mL after initial viral suppression or unreached
viral suppression 6 months after therapy initiation.
With respect to time to viral suppression, the plasma HIV-1 log10 RNA level is assumed to
decline linearly from the current value until reaching the value 0.5 (corresponding approxi-
mately to 3 plasma HIV-1 RNA copies/mL) at the estimated time, and is kept constant until
virologic failure. Plasma HIV-1 log10 RNA rebound levels for virologic failure are sampled
from a uniform distribution, with parameters calibrated on observational data [34]. Mean-
while, the evolution of CD4+ T cell counts is governed automatically by the basic HIV-D
model. Patients may switch regimens for reasons other than virologic failure an unlimited
number of times within each treatment line. When a regimen switch due to virologic failure
occurs, patients move to a subsequent treatment line. Upon regimen switch due to virologic
failure on third-line treatment, patients loop back to this treatment line as many times as neces-
sary until resistance reaches the highest class, regardless of the number of virologic failures.
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Once the highest resistance class is reached upon line switch, individuals start non-suppressive
therapy.
Resistance levels are grouped into four classes, according to the inverted Genotypic Sensitiv-
ity Score [34, 50] and it is assumed that patients can move only to an adjacent, higher resistance
class because resistance is archived in cellular DNA. Upon reaching the time to (new) resis-
tance development, resistance levels are sampled uniformly from within each class. Adherence
evolves over time based on a generalized linear model. Regimen characteristics are updated on
occurrence of line and regimen switches.
Non-Suppressive Therapy. Upon reaching non-suppressive therapy, the plasma HIV-1
log10 RNA level is set to a value sampled from a normal distribution with parameters calibrated
on observational data [31]c. After this, modeling of CD4+ T cell counts and plasma HIV-1
RNA levels is returned back to the HIV-D model. As a result of the increasing total viral bur-
den, plasma HIV-1 RNA levels keep increasing whereas CD4+ T cell counts start dropping to
AIDS-defining levels, in turn increasing mortality risk.
Costs. The model considers monthly ART and non-ART costs, both based on generalized
linear models, which are updated upon regimen switch and changes in resistance level.
Monthly non-ART costs include in addition, among others, physician appointments, exams
and laboratory tests [34].
Mortality and Quality of Life
Before, it was argued how, during the acute stage of the infection CD4+ T cell counts initially
drop and then increase rapidly, however never returning to pre-infection levels. If untreated,
the subsequent clinical latency stage of the infection is characterized by a slow depletion of
CD4+ T cells until reaching AIDS-defining levels, typically about 8–10 years after seroconver-
sion. If treated, CD4+ T cell counts grow slowly, but again usually do not reach pre-infection
levels.
Studies show that mortality is CD4+ T cell count dependent and, even after ART initiation,
remains higher in HIV-1 infected individuals than in the general population [51]. For HIV-1
infected individuals with CD4+ T cell counts below 200 cells/mm3, a 30-fold increase in (age
and gender standardized) mortality rates has been estimated, whereas for patients with CD4+ T
cell counts above 500 cells/mm3, this is reduced to a 2.5-fold increase [51].
At model initiation, the life expectancy of each simulated individual is sampled from mor-
tality tables of the general population. Instantaneous HIV-1 infection related excess mortality
as compared to the general population is implemented using CD4+ T cell count-dependent
standardized mortality ratios (SMR, Table 5) [51]. The model is completely flexible with
respect to SMR, easily adaptable as more data on the true impact of life expectancy is acquired.
In order to keep the total population-size constant, each time an individual dies, a new, unin-
fected individual is generated, aged 13-years old (considered the minimum age for onset of sex-
ual availability) [32].
Table 5. Standardized mortality ratios for excessmortality due to HIV-1 infection.
Parameter CD4+ T cell count Value
Standardized Mortality Ratio 500 cells/mm3 2.5
500 cells/mm3–350 cells/mm3 3.5
350 cells/mm3–200 cells/mm3 5.6
<200 cells/mm3 30.3
doi:10.1371/journal.pone.0149007.t005
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Given the variable nature of CD4+ T cell counts (disease progression and ART dependent)
in the model, it is easily understood that CD4+ T cell counts are one of the main drivers of mor-
tality in EPICE-HIV.
Similarly, CD4+ T cell-dependent quality of life (QoL) utilities are considered for cost-effec-
tiveness modeling in terms of quality adjusted life years (QALY). Two sets of utilities are con-
sidered: one for plasma HIV-1 RNA suppressed individuals, and another for unsuppressed
individuals (Table 6) [49].
External Model Validation
Due to the complexity and comprehensiveness of the EPICE-HIV model as a whole, compo-
nents that have been previously validated or described in the literature are not presented nor
discussed. Though constituting a limitation to the current paper, validation within EPICE-HIV
of these model components will be addressed in future work. The secondary treatment regimen
part of the within-host model and the transmission module have previously been discussed in
detail within comparable contexts [32, 34]. As such, the present analysis focuses on the HIV-D
model and the implementation of the primary treatment regimen in the within-host model.
To strengthen the external validity of the HIV-D model, a simulation study was performed
to allow comparisons to the data from the RPV/FTC/TDF arm of the STaR study [33]. The
STaR study was a phase 3b, randomized, multicenter, international, open-label, 96-week clini-
cal trial comparing the safety and efficacy of two single-tablet regimens, RPV/FTC/TDF and
EFV/FTC/TDF, in 786 ART-naive, HIV-1 infected patients. Full validation against STaR study
results, also including once-daily treatment with coformulated EFV/FTC/TDF will be dis-
cussed in an upcoming paper. In future work, the validation of the model against data from
observational studies will also be considered.
The simulation consisted of 100,000 hypothetical infected individuals, initiating first-line
ART with once-daily, coformulated RPV/FTC/TDF, using the same set of conditions in terms
of baseline characteristics, clinical management and efficacy criteria of the STaR study [5]. We
tested the hypothesis if the HIV-D model component of EPICE-HIV would be able to accu-
rately produce 96-week percentages of virologically suppressed patients (as determined by the
FDA Snapshot algorithm), qualitatively and quantitatively comparable to the percentages
observed in the STaR study [33], and what effect alternative adherence distributions have on
the results.
Results and Discussion
HIV-1 Dynamics Model
Disease Progression. As an independent module, in the absence of drug effect, the HIV-D
model simulates CD4+ T cell counts and plasma HIV-1 RNA levels as a function of time for
Table 6. Quality of life utilities for cost-effectivenessmodeling.
Parameter CD4+ T cell count Suppressed Unsuppressed
QoL Utility 500 cells/mm3 0.954 0.938
500 cells/mm3–350 cells/mm3 0.934 0.931
350 cells/mm3–200 cells/mm3 0.929 0.932
200 cells/mm3–50 cells/mm3 0.863 0.849
<50 cells/mm3 0.781 0.781
doi:10.1371/journal.pone.0149007.t006
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HIV-1 infected individuals that pass through the 3 typical stages of HIV-1 infection: acute
infection, clinical latency and AIDS phase (Fig 3) [52].
The HIV-D model is capable of reproducing not only the acute stage of HIV-1 infection,
but also the slow depletion of CD4+ T cells and increase in viral load typical of the clinical
latency stage. In the simulated example, after about 8 years from seroconversion, the CD4+ T
cell count steadily declines, reaching the value of 200 cells/mm3 at 9.7 years after infection.
Drug Potency. In Fig 4 the evolution of the CD4+ T cell count and plasma HIV-1 RNA
levels is presented as a function of time for a patient starting ART 8 years after seroconversion
with hypothetical continuous drug potency ε = 100%,.
After treatment initiation, the CD4+ T cell count grows slowly, but does not reach the pre-
infection level of 1000 cells/mm3. This is a consequence of the inclusion of disease progression
in the model, as previously mentioned. The decline in plasma viral load follows the three
phases described before. A sharp drop in viral load occurs within the first two weeks of ART,
determined mainly by the decay rate of productively infected activated CD4+ T cells (T2).
Afterwards the viral load keeps declining, but at a much slower rate (decay rate of latently
infected CD4+ T cells). The threshold of 50 plasma HIV-1 RNA copies/mL is reached after 2
months, but can be adjusted depending on the family of antiretroviral drugs used. Viral persis-
tence at a level of about 2 plasma HIV-1 RNA copies/mL (considered for this particular exam-
ple) is set in approximately 1 to 1.5 years after treatment initiation.
The grey dashed-dotted line in the left-hand side graph of Fig 4 represents the evolution of
the viral load when the persistent low level viremia adjustment to the HIV-D model is ignored.
The second-phase decline then takes the viral load to unreliable levels, demonstrating the need
for explicit persistent low viremia modeling.
Primary Treatment Regimen
Adherence to Therapy. Using the binary first-order autoregressive adherence model, Fig
5 shows there is not only a strong correlation between the theoretical desired average adherence
and the final observed simulated average adherence, but there is also a relationship between the
longer treatment interruption and the observed average adherence, quantitatively and qualita-
tively comparable to the one found in Parienti et al. (2010) [45]. The simulation is based on a
random sample of 100 hypothetical individuals followed for over a 1-year time period, with
Fig 4. Evolution of plasma HIV-1 RNA levels and CD4+ T cell counts in a treated subject. Left: plasma HIV-1 RNA levels as a function of time, simulated
by the HIV-D model with drug effect, when persistent (black line) and non-persistent (grey dashed-dotted line) low level viremia are considered. The
horizontal grey dashed line corresponds to the common viral load detection threshold of 50 plasma HIV-1 RNA copies/mL, whereas the horizontal grey
dotted line corresponds to a theoretically imputed persistent low level viremia of 2 plasma HIV-1 RNA copies/mL (considered for this particular example).
Right: corresponding CD4+ T cell counts. Simulated treatment with hypothetical continuous drug potency ε = 100% starting at 8 years after seroconversion.
doi:10.1371/journal.pone.0149007.g004
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theoretical average adherence distribution: 30% with adherence below 80%; 20% with adher-
ence between 80% and 90%; and 50% with adherence above 90% [45].
PK/PDModeling. The results presented below focus on a once-daily, triple combination
therapy with coformulated rilpivirine 25mg (RPV), emtricitabine 200mg (FTC) and tenofovir
DF 245mg (TDF) and are based on PK parameters from Table 7.
The logarithmic measure of inhibition (Fwt), was calculated as a function of drug concentra-
tion (log-scale percentage of maximum concentration, Fig 6) for RPV, FTC and TDF. At clini-
cal concentrations, immediately to the left of the vertical grey dashed line, neither of the
individual drugs attains a value larger than 5, suggested as a minimum threshold for successful
HAART [46]. Predictions are also presented for the combined inhibition effect of RPV+FTC
+TDF by the Bliss independence, Loewe additivity and DImodel. For the DImodel, a hypo-
thetical index 0.5 of degree of independence was assumed. Intermediate inhibition can be
defended for NNRTI-NRTI interactions [49]. For the Bliss independence and DImodel predic-
tions, inhibition values are above 5. For the Loewe additivity model predictions, inhibition val-
ues are mainly driven by the NNRTI component (RPV) of the ART regimen.
On the right-hand side of Fig 6, corresponding logarithmic measures of inhibition are pre-
sented as a function of days, for an EPICE-HIV simulated patient, 100% adherent to therapy,
except for a treatment interruption of 15 days, starting at day 50. During this treatment inter-
ruption, inhibition is seen to drop fast, ultimately approaching the level of 50% inhibition (hor-
izontal grey dashed line), suggesting an increase in viral replication. At the end of the
treatment interruption, the decline in inhibition effect seems to slow down slightly, owing
Fig 5. Simulated average adherence and treatment interruption duration. Left: Correlation between the theoretical average adherence and simulated
observed average adherence, obtained with the first-order binary autoregressive adherence model, for a random sample of 100 hypothetical individuals
followed for a 1-year time-period. Theoretical average adherence distribution: 30% with adherence below 80%; 20% with adherence between 80% and 90%;
50% with adherence above 90%. Right: Relationship between simulated observed average adherence and corresponding longer treatment interruption, for
the same random sample.
doi:10.1371/journal.pone.0149007.g005
Table 7. PK/PDmodeling parameters for RPV, FTC and TDF.
Parameter RPV [48, 53] FTC [49] TDF [48, 49]
Cmax 0.378 μMol 6.8 μMol 1.06 μMol
IC50 0.0039 μMol 0.0112 μMol 0.013 μMol
t1/2 45 h 39 h‡ 60 h‡
m 1.92 0.92 0.42
‡ Intracellular
doi:10.1371/journal.pone.0149007.t007
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mainly to the lower slope parametersm of the NRTI. As can be seen further, after the reintro-
duction of therapy, it takes about another 15 days for the inhibition effect to converge back to
its periodic orbit, prolonging the impact of the treatment interruption on inhibition.
Jilek et al. (2012) [49] further investigated the correlation between clinical outcomes of RCT
and IIP values of different drugs and drug combinations, suggesting that for ART regimens
with low IIP, the percentage of patients with plasma HIV-1 RNA levels below 50 copies/mL at
48 weeks is correlated to the estimated IIP of the considered regimen. For ART regimens with
high IIP, on the other hand, it is argued that little correlation with outcome can be detected,
suggesting that at high IIP levels, viral replication is mostly halted and outcomes depend
mainly on adherence to therapy.
Combining the Adherence, PK/PD and HIV-DModels. To demonstrate the interaction
of the first-order binary autoregressive adherence model with the PK/PD model and HIV-D
model within EPICE-HIV, a simulated patient was considered, starting coformulated RPV/
FTC/TDF 8 years after seroconversion and followed-up for 2 years. For the purpose of this par-
ticular simulation, a theoretical persistent low level viremia of 10 plasma HIV-1 RNA copies/
mL was considered and an index of degree of independence DI of 0.5 was assumed. During the
first year of therapy the patient was simulated to be 100% adherent, allowing for RPV/FTC/
TDF to be successful in controlling plasma HIV-1 RNA levels below 50 copies/mL (Fig 7).
After the first year of therapy, adherence was allowed to be driven by the first-order binary
autoregressive adherence model. During the second year of therapy, the patient demonstrated
an average adherence of 76%, leading to two major continuous treatment interruptions (Fig 7,
black squares). The first occurred just before 9.6 years, with a duration of 15 days. The second
occurred around 9.9 years, with a duration of 24 days. The 15 day treatment interruption leads
to drug concentrations that allow for viral replication, showing a small increase in plasma
HIV-1 RNA levels (Figs 6 and 7). The treatment interruption is not long enough though, to
warrant detection at a 50 copies/mL threshold. The 24 day interruption, on the other hand, is
long enough for plasma HIV-1 RNA levels to rise not only above 50 copies/mL, but also above
400 copies/mL. Furthermore, several days after the reintroduction of treatment, viral load levels
remain detectable by the 50 copies/mL threshold, owing to the time it takes for viral inhibition
to converge back to its desired levels.
Fig 6. Drug inhibition as a function of drug concentration and time. Left: Logarithmic measure of inhibition (Fwt) as a function of drug concentration
(percentage of maximum concentration, log10-scale), for drugs RPV, FTC and TDF alone (green lines) and predictions of the combined effect of RPV+FTC
+TDF by the Bliss, Loewe and DI model. For the DI model, a hypothetical index 0.5 of degree of independence was assumed. The vertical grey dashed line
represents the inhibition potential at maximum concentration for all three drugs. Right: Logarithmic measure of inhibition (Fwt) as a function of days, based on
the Bliss, Loewe and DI model combined effect predictions. Simulations are representative of triple combination ART initiation with RPV+FTC+TDF, for a
patient 100% adherent to therapy, except for a treatment interruption of 15 days, starting at day 50. After 15 days, a level of only 50% inhibition, represented
by the horizontal grey dashed line, starts being approached.
doi:10.1371/journal.pone.0149007.g006
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A previous logistic model has estimated a 90% probability of virologic rebound (plasma
HIV-1 RNA 400 copies/mL) associated to treatment interruptions of 24 days for NNRTI-
based ART with comparable follow-up, making results observed at the end of the simulated
two-year treatment period in Fig 7 more than plausible [54]. For treatment interruptions of 15
days, the estimated probability of virologic rebound was 50%.
Further simulations have shown that if persistent levels of viremia are set higher (e.g.: closer to
40 copies/mL), a similar adherence pattern leads to plasma HIV-1 RNA levels above 50 copies/
mL at the end of a 15 day treatment interruption. This highlights the importance of correct
modeling of low level viremia. Even with lower levels of persistent viremia, if several small, closely
interspaced treatment interruptions would precede the longer 15 day treatment interruption,
plasma HIV-1 RNA levels would likely be low, but uncontrolled before the start of the 15 day
interruption, augmenting the probability of virologic rebound at the end of the interruption. This
suggests that not only the duration of treatment interruptions, but also their inter-location is
important. Both situations occur in a natural way within EPICE-HIV, making virologic rebound
at 400 copies/mL plausible for a 15 day treatment interruption, under the right circumstances.
Using the STaR Trial for External Model Validation
The main results comparing the simulated 96-week percentages of virologically suppressed
EPICE-HIV simulated patients initiating first-line ART with RPV/FTC/TDF to the corre-
sponding percentages observed in the STaR study [33], can be found in Table 8.
STaR trial data comprises the full analysis set (FAS) and a modified analysis set (MAS),
excluding patients with missing data at 96 weeks. The FAS population consists of the 394
patients randomized to and treated with RPV/FTC/TDF. Because our model provides exhaus-
tive virologic information (no missing data) MAS results are also considered for comparability
reasons. EPICE-HIV simulations are based on the adherence distribution from the STaR study
(‘Base Case’) and an alternative adherence distribution (‘Alternative’, details below) to account
for potential bias arising from self-reported adherence.
Fig 7. Treatment interruptions and viral response. Left: Plasma HIV-1 RNA levels as a function of time, simulated by the HIV-D model with drug effect
modeled by the primary treatment regimenmodule of EPICE-HIV. The treatment considered is RPV/FTC/TDF, starting at 8 years after seroconversion with a
theoretically imputed persistent low viremia level of 10 plasma HIV-1 RNA copies/mL. For comparability with Parienti et al. [45, 54] during the first year of
therapy, 100% adherence was assumed, allowing for plasma HIV-1 RNA levels to be controlled (below 50 copies/mL). After that, adherence to therapy is
driven by the first-order binary autoregressive adherence model. In the second year of therapy, the patient demonstrated 76% of adherence. Right: Close-up
of the last half year of therapy, demonstrating two large treatment interruptions, represented by black squares: one of 15 days (around 9.6 years) and another
of 24 days (around 9.9 years). The horizontal grey dashed and dotted lines correspond to viral load detection thresholds of 50 and 400 plasma HIV-1 RNA
copies/mL, respectively. Though the 15 day interruption leads to drug concentrations that allow for viral replication, it is not long enough for plasma HIV-1
RNA levels to rise above the detection thresholds. The 24 day interruption leads to plasma HIV-1 RNA levels above 400 copies/mL. Several days after
reintroduction of treatment, levels remain detectable by the 50 copies/mL threshold.
doi:10.1371/journal.pone.0149007.g007
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Comparing the EPICE-HIV estimates in the base case with the MAS results of the STaR
study, most of the observed differences are a direct consequence of a slightly lower rate of viro-
logic failure in the simulated data. At week 96, a smaller percentage of simulated cases had viral
loads50 copies/mL than in the STaR study (0.3% vs 1.6%). Similarly, discontinuations due to
lack of efficacy showed a smaller percentage in the simulated population (1.0%) than in the
STaR population (4.1%). Furthermore, also a smaller percentage of patients discontinuing due
to other reasons had uncontrolled viral loads in the simulated data (2.7%) as compared to the
STaR study (3.9%).
Overall, a virologic success rate of 82.7%, a virologic failure rate of 4.0% and a rate of
absence of virologic data of 13.3% was simulated, compared to the rates of 79.3%, 9.6% and
11.1% in the MAS STaR trial data, respectively. The largest difference observed is with respect
to the rate of virologic failure and is the only one reaching statistical significance (risk differ-
ence: -5.5%; 95%CI [-8.5%;-2.6%]) (Table 9).
These observed differences might be related to multiple factors, an important one of which
may be adherence. Adherence in the STaR study was determined through the Medication
Adherence Self Report Inventory (MASRI) questionnaire, completed by study subjects. Studies
on the relationship between self-reported adherence, electronically monitored adherence and
virologic success [17, 18, 55] have suggested that self-reported adherence is generally higher
than electronically monitored adherence and the likelihood of achieving virologic success is
greater if electronically monitored adherence is high than if self-reported adherence is high.
Differences of over 20% in average adherence when comparing self-reported to electronically
monitored adherence can be found in the literature.
Though in a clinical trial setting, with a population less representative of the general popula-
tion, this effect might be attenuated, it should not be ignored all together when simulating.
Adherence in the STaR study was generally very high (average 96.8%) even after 96 weeks of
treatment, with few patients demonstrating adherence levels below 80%. To test the hypothesis
of the effect of the adherence distribution on the EPICE-HIV results, a second scenario was set
up, considering an alternative distribution with an average 5% decrease in adherence as com-
pared to the adherence data observed in the STaR study (Table 8).
Table 8. Week 96 snapshot analysis for the RPV/FTC/TDF arm of the STaR study [33] and the simulated population in the EPICE-HIV model:
detailed results.
STaR Trial Data EPICE-HIV Simulation
FAS MAS Base Case Alternative
Virologic Success at Week 96 77.9% 79.3% 82.7% 78.6%
HIV-1 RNA < 50 copies/mL 77.9% 79.3% 82.7% 78.6%
Virologic Failure at Week 96 9.4% 9.6% 4.0% 8.5%
HIV-1 RNA  50 copies/mL 1.5% 1.6% 0.3% 0.7%
Discontinued study drug due to lack of efﬁcacy 4.1% 4.1% 1.0% 5.1%
Discontinued study drug due to other reasons and last available HIV-1 RNA  50 copies/mL 3.8% 3.9% 2.7% 2.7%
No Virologic Data in Week 96 Window 12.7% 11.1% 13.3% 12.9%
Discontinued study drug due to AE or death 3.0% 3.1% 3.3% 3.3%
Discontinued study drug due to other reasons and last available HIV-1 RNA < 50 copies/mL 7.9% 8.0% 10.0% 9.7%
Missing data during window but on study drug 1.8% 0.0% 0.0% 0.0%
FAS: Full analysis set; MAS: Modiﬁed analysis set (excludes patients on treatment, but with missing data during 96 week window; Base case:
Simulations performed with the adherence distributions observed in the STaR study; Alternative: Simulations performed with alternative hypothetical
adherence distributions, adjusting for possible bias in self-reported adherence.
doi:10.1371/journal.pone.0149007.t008
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The results suggest a higher rate of virologic failure as compared to the base case scenario,
relating better to the results observed in the MAS population (Table 9). Individual differences
can be interpreted as an effect of timing in treatment interruptions. Overall, 5.7% of the STaR
population (MAS) suffered treatment failure (discontinuing study drug due to lack of efficacy,
or50 plasma HIV-1 RNA copies/mL) at week 96. For the simulated population, the alterna-
tive scenario would result in an estimate of 5.8%, closer to observed values than the 1.3% esti-
mated in the base case.
In conclusion, using a fine-tuned multi-paradigm micro-simulation model, we were able to
approximate the 96 week outcomes of subjects treated with coformulated RPV/FTC/TDF in
the randomized STaR study.
Practical Implications
With EPICE-HIV, we have argued and demonstrated that adherence to ART is an important
driver of clinical and therapeutic outcomes in HIV-1 infected individuals. For optimal out-
comes, high levels of adherence are required. Suboptimal adherence levels can have serious
clinical, economic and epidemiologic implications.
Systematic lack of adherence to ART may lead to an increase in viral replication, especially–
but not only–for therapies with short PK half-lives. On the one hand, increased viral replication
is associated with reduced immunological response of patients, impacting the economic burden
of the disease, quality of life and mortality. On the other hand, it also increases the risk of dis-
ease transmission, posing a clear public health issue. Consequently, from a health policy per-
spective, EPICE-HIV may be valuable in assessing and identifying optimal HIV-1 health care
strategies—particularly those related to improving adherence—in a very comprehensive way.
EPICE-HIV further demonstrates that even small changes to adherence can affect clinical
and economic outcomes, not only on the short-term, but also on the long-term, potentially
changing the relative value of different therapy options. Given the difference in adherence typi-
cally observed between clinical practice and clinical trials, from a health technology assessment
and cost-effectiveness perspective, EPICE-HIV may aid in defining the real-world clinical and
economic value of different ART regimens for decision makers.
In the light of this, validation of EPICE-HIV against observational study data, which are
more representative than randomized controlled trial data for the analysis of real-world clinical
settings, should further strengthen the external validation of the model. This limitation to the
current paper will be addressed in future work.
Table 9. Week 96 snapshot analysis for the RPV/FTC/TDF arm of the STaR study [33] and the simulated population in the EPICE-HIV model: risk
differences between simulated and observed results.
STaR Trial Data EPICE-HIV Simulation
MAS Base Case Alternative
Virologic Success at Week 96 79.3% 82.7% 78.6%
Risk difference—% (95% CI) 3.3% [-0.7%;7.4%] -0.7% [-4.8%;3.3%]
Virologic Failure at Week 96 9.6% 4.0% 8.5%
Risk difference—% (95% CI) -5.5% [-8.5%;-2.6%] -1.1% [-4.0%;1.9%]
No Virologic Data in Week 96 Window 11.1% 13.3% 12.9%
Risk difference—% (95% CI) 2.2% [-1.0%;5.4%] 1.8% [-1.3%;5.0%]
MAS: Modiﬁed analysis set (excludes patients on treatment, but with missing data during 96 week window; Base case: Simulations performed with the
adherence distributions observed in the STaR study; Alternative: Simulations performed with alternative hypothetical adherence distributions, adjusting
for possible bias in self-reported adherence.
doi:10.1371/journal.pone.0149007.t009
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